LAG3 and melanoma: In this line, FDA recently approved the combination therapy of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3 mAb, Opdualag), which was shown to provide a greater benefit with regard to progression-free survival than inhibition of PD-1 alone, in patients with previously untreated metastatic or unresectable melanoma (REALITIVY-047, ClinicalTrials.gov number, NCT03470922) (101).